Transvaginal Ultrasound for Early Ovarian Cancer Detection

What is a Transvaginal Ultrasound Test for Ovarian Cancer?

A transvaginal ultrasound (TVUS) is the primary imaging method used to evaluate adnexal masses that may be suspicious for ovarian cancer. This test employs high-frequency sound waves (5-9 MHz) delivered through an endovaginal probe, which is gently inserted 1-2 cm into the posterior vaginal fornix. TVUS provides better visualization of ovarian structures compared to transabdominal ultrasound, allowing for the differentiation between benign simple cysts and malignant complex masses by assessing features such as cyst wall thickness, the presence of septations, papillary projections, and vascularity through Doppler color flow mapping. When combined with the CA-125 blood test, TVUS achieves a sensitivity of 85-95% and a specificity of 90-98% for detecting malignancy in postmenopausal women, aiding in making surgical referral decisions according to ACOG/SGO guidelines.

How Does a Transvaginal Ultrasound Detect Ovarian Cancer?

Patient Preparation: The patient is advised to empty her bladder prior to the procedure; no fasting is required. The test is conducted in the lithotomy position and usually lasts about 10 minutes, with a chaperone present for comfort.

• •Step 1 - Probe Insertion
  A curvilinear endocavitary transducer (7-10 cm in length), covered with gel or a condom, is gently inserted to provide real-time 2D grayscale imaging of the ovaries, uterus, and cul-de-sac.
• •Step 2 - Ovarian Assessment
  A systematic survey documents ovarian volume (greater than 20 cc in postmenopausal women indicates suspicion), characteristics of cysts (unilocular vs. multilocular, septation thickness greater than 3 mm, wall irregularity), and identification of solid components (greater than 1 cm³).
• •Step 3 - Doppler Evaluation
  Power/color Doppler techniques are used to measure the resistive index (RI less than 0.4 suggests malignancy), peak systolic velocity (greater than 20 cm/s is considered suspicious), and the vascular distribution pattern (central branching).
• •Step 4 - IOTA Rules Application
  The IOTA Simple Rules (M-features: multilocular, solid areas, metastatic lesions, ascites; B-features: unilocular, smooth walls, no blood flow) or the Simple Descriptor Index are utilized to stratify the risk of malignancy with 95% specificity.

Transvaginal Ultrasound Findings in Ovarian Cancer

• •Early-Stage (Stage I)
  Findings may include unilocular-solid cysts (50%), multilocular cysts with thin septations (less than 3 mm), minimal wall nodularity, and moderate vascularity (RI 0.4-0.6), with a sensitivity of 85%.
• •Advanced-Stage (Stage III/IV)
  Characteristics often include moderate-to-large solid components (greater than 2 cm), thick irregular septations (greater than 3 mm), papillary projections, central vascularity (RI less than 0.4), ascites, and omental caking, yielding a sensitivity of 95% but a specificity of only 70%.
• •Borderline Tumors
  These typically present as predominantly multilocular cysts with thin avascular septations and small wall papillae (less than 10 mm), showing a low-risk Doppler pattern.

Transvaginal Ultrasound by Ovarian Cancer Stages

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

• •Stage I
  Ovarian-confined complex cysts (solid-cystic morphology, RI 0.45-0.55) may be present, with the capsule intact and no pelvic free fluid.
• •Stage II
  Pelvic extension with cul-de-sac fluid and uterine serosal implants may be visible adjacent to the mass; Doppler confirms hypervascularity.
• •Stage III
  Upper abdominal ascites and omental studding may appear as echogenic peritoneal masses; sensitivity drops to 70% for microscopic peritoneal disease.
• •Stage IV
  Pleural effusion may correlate with massive pelvic masses, with detectable liver surface lesions, though parenchymal invasion requires CT or MRI for confirmation.

First Transvaginal Ultrasound After Ovarian Cancer Treatment

Post-treatment surveillance can detect recurrence 6-12 months earlier than using CA-125 or CT alone. For high-risk stage III/IV patients, follow-up at three-month intervals is recommended during the first two years, according to NCCN/SGO guidelines. A baseline ultrasound is typically performed 4-6 weeks after cytoreduction to assess for postoperative ovarian remnants or adhesions, while serial exams monitor for new solid nodules, reaccumulation of ascites, or bowel wall thickening that may signal peritoneal progression. The frequency of follow-ups may decrease to every six months in years three to five and then annually; a rise in lesion volume (greater than 20% increase) or a decline in RI (less than 0.4) will prompt a PET-CT or diagnostic laparoscopy.

Why Choose Everhope for Your Ovarian Cancer Transvaginal Ultrasound Test?

Everhope Oncology employs IOTA-certified sonographers who achieve good specificity using 3D power Doppler and elastography. We also provide integration of ROMA/OVA1 blood tests for immediate surgical triage and direct ultrasound findings to molecular tumor board reviews for precision therapy planning.